December 18, 2019 | Benzinga
Medical cannabis product manufacturerPanaxia Labs Israel reportedpositive results Wednesday from a clinical trial that evaluated the bioavailability and safety of several new delivery methods for its medical cannabis products.
The trial successfully met its primary objectives, the company said.
The results showed the efficacy of absorption in the blood and safety of tablets, suppositories and inhaled cannabis extract, according to Panaxia Labs.
Panaxia said it plans to obtain regulatory approval for various formats of its products in Israel and some European countries.
The company’s sublingual tablets have a better absorption rate and lower variance than the industry’s gold standard, Sativex, according to Panaxia.
Read More On: Benzinga Website